5 Annual Meeting.

During the year, over 290,000 healthcare professionals were reached through education, training and medical awareness activities,5including the Galderma Aesthetic Injector Network (GAIN) – which celebrated its 10thanniversary in 2025 – the Global Sensitive Skincare Faculty (GSSF), and the Skin Knowledge and Innovation Network (SKIN).

Financial scorecard

For the full year 2025, Galderma delivered 1,211 million USD in Core EBITDA, up 18.9% year-on-year at constant currency. The reported Core EBITDA margin was 23.3%, representing a margin expansion of 24 basis points at constant currency compared to 2024. Core EBITDA grew ahead of net sales, in a year of major launches with reinvestments into growth, thanks to ongoing operating leverage as well as a reduced adverse P&L impact from nemolizumab as a result of greater sales. Improvements in operating expenses also offset the impact of pricing effects and unfavorable product mix
=*=*=*=*=*=
当前为第17/55页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页